Efficacy and Safety of Oral BT-11 in Mild to Moderate Ulcerative Colitis
Status:
Completed
Trial end date:
2021-06-17
Target enrollment:
Participant gender:
Summary
This is a phase 2 randomized, placebo-controlled, double-blind, parallel-group multicenter
study with an optional open-label extension (OLE) period. The purpose of this study is to
evaluate the efficacy and safety of oral BT-11 compared to placebo in subjects with mild to
moderate UC. This study includes 3 periods: induction, maintenance, and an optional OLE
period.